The latest news for pharma industry insiders.

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses observations in enterprise value growth and enterprise value-to-sales ratios among top biopharmaceutical companies.

Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report.

The latest news for pharma industry insiders.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses "Enhancing Patient Access and Support Through Technology: A Comprehensive Assessment," and upcoming industry challenges.

The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia.

The latest news for pharma industry insiders.

A panel examines the gross-to-net bubble across various product mixes, how pricing impacts market access, and more.

Kevin O’Meara discusses how patient service teams influence adherence from Direct-to-Patient models.

The latest news for pharma industry insiders.

In the fourth part of this roundtable discussion, key opinion leaders discuss how successful RFID use cases in the food sector can translate well to pharma, including what needs to be implemented in order to see success.

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the breakout session at Trade & Channel Strategies in Philadelphia.

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

A session investigates the drivers of these shortages and ways to mitigate them.

The latest news for pharma industry insiders.

Breakout session explores how direct-to-patient models shorten the time to diagnosis and therapy to improve patient outcomes.

The seminar focuses on US supply chain resiliency, while remaining compliant and preserving patient access.

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

The latest news for pharma industry insiders.

A panel uncovers how distribution channels are aligning commercialization efforts.

Conference keynote speech examines the industry’s critical developments of 2024 and offers a strategic outlook for next year.

The latest news for pharma industry insiders.

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

A cohort study of cancer drugs analyzes where the priorities of pricing policies should lie.